Analyst Josh Jennings of TD Cowen maintained a Buy rating on Humacyte, retaining the price target of $3.50.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Josh Jennings has given his Buy rating due to a combination of factors that highlight Humacyte’s promising advancements and strategic positioning in the vascular therapy market. The company’s recent performance at the VEITH symposium underscored the clinical momentum of their Symvess platform, which has shown significant potential in regenerative biology and high-acuity trauma applications.
Humacyte’s ability to present a wide array of evidence supporting Symvess as a regenerative vascular conduit across various indications was a key factor in Jennings’s positive outlook. The symposium provided a valuable opportunity for the company to engage with leaders in vascular surgery and endovascular therapy, thereby enhancing their clinical outreach and setting the stage for future trial recruitment and market adoption. These developments collectively suggest a strong growth trajectory for Humacyte, justifying the Buy rating.
In another report released on November 13, Benchmark Co. also maintained a Buy rating on the stock with a $11.00 price target.